GeNeuro presents Phase2B data demonstrating neuroprotective effect of GNbAC1 in Multiple Sclerosis Patients at ECTRIMS 2018

GeNeuro presents Phase2B data demonstrating neuroprotective effect of GNbAC1 in Multiple Sclerosis Patients at ECTRIMS 2018

. Positive effects observed on key neuroprotection endpoints related to MS disease progression

. Neuroprotective effects also seen in non-active MS patient

. Confirmation of safety and tolerability

Geneva, Switzerland, and Berlin, Germany, 15 October, 2018 – 7:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that data from its CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS), demonstrating a consistent effect on key neuroprotection endpoints was presented at the 34th Congress of the European Committee for Treatment and Research on Multiple Sclerosis (ECTRIMS 2018).

More information on : https://www.newcontact.eu/secure/media/com_newcap/files/files/Geneuro%20ECTRIMS18%20Data%20PR%20ENG%20VF151018.pdf